|
KMID : 1039320160160010057
|
|
Journal of Liver Cancer
2016 Volume.16 No. 1 p.57 ~ p.62
|
|
|
Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
|
|
김대하:Kim Dae-Ha
민지호:Min Gee-Ho/이동원:Lee Dong-Won/안계련:Ahn Ke-Ryun/김지혜:Kim Ji-Hye/서상준:Suh Sang-Jun/정영걸:Jung Young-Kul/임형준:Yim Hyung-Joon
|
|
|
Abstract
|
|
|
|
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.
|
|
|
KEYWORD
|
|
|
Carcinoma, Hepatocellular, Drug therapy, Sorafenib, Treatment outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|